Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.63 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.63 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963252 | 0.85 | SLC6A9 (0.67) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL1138302 | 0.81 | SLC6A9 (0.58) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL1138335 | 0.80 | SLC6A9 (0.56) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL5562056 | 0.79 | SLC6A9 (1.00) | SLC6A9OPRM1SLC6A5OPRL1 | |
| SCHEMBL1138219 | 0.78 | SLC6A9 (1.00) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL5556394 | 0.78 | SLC6A9 (1.00) | SLC6A9OPRM1OPRL1KCNH2 | |
| SCHEMBL16714470 | 0.78 | SLC6A9 (1.00) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL5557027 | 0.78 | SLC6A9 (1.00) | SLC6A9OPRM1OPRL1KCNH2 | |
| SCHEMBL1138222 | 0.78 | SLC6A9 (1.00) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL4334410 | 0.78 | SLC6A9 (0.53) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025690-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-7597884-B2 | Hyperglycosylated polypeptide variants and methods of use | ALIOS BIOPHARMA, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7597884-B2 | Hyperglycosylated polypeptide variants and methods of use | ALIOS BIOPHARMA, INC. (US) | 2009-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | SLC6A9 3427/4885OPRM1 52/4885SLC6A5 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.